Elan to suspend trading during FDA product review for Tysabri

By Elaine Rigoli

Tampa, Fla., Feb. 28 - Elan Corp. plc announced Tuesday it has agreed with the Irish Stock Exchange (ISE), the Financial Services Authority in the United Kingdom and the New York Stock Exchange to suspend trading of its securities, including ADRs and ordinary shares, during the scheduled Food and Drug Administration advisory committee meeting to review Tysabri.

On March 7, trading will be suspended for two days on the NYSE and will be suspended on the ISE and London Stock Exchange from 1 p.m. GMT to coincide with the start of the advisory committee meeting, according to a company news release.

When the advisory committee meeting is complete, the company will request the stock exchanges to resume trading.

Elan, based in Dublin, Ireland, is a neuroscience-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.